

CURRICULUM VITAE

Name: Alan Michael Krensky

Address: Department of Pediatrics
Stanford University School of Medicine
Stanford, California 94305-5208

Telephone: (650) 498-6073

Telefax: (650) 498-6077

E-mail krensky@stanford.edu

Date of Birth: October 12, 1951

Place of Birth: Chicago, Illinois

EDUCATION

1973 B.A. University of Pennsylvania, Summa cum Laude
1977 M.D. University of Pennsylvania

POSTDOCTORAL TRAINING

Internship and Residencies:

1977-1978 Internship in Medicine, Children's Hospital Medical Center,
Boston, MA
1978-1979 Junior Resident, Children's Hospital Medical Center, Boston, MA
1979-1980 Senior Resident, Children's Hospital Medical Center, Boston, MA

Fellowships:

1980-1981 Clinical Fellow, Pediatric Nephrology, Children's Hospital Medical
Center, Boston, MA
1981-1983 Research Fellow, Pediatric Nephrology & Immunology, Children's
Hospital Medical Center & Sidney Farber Cancer Institute, Boston, MA

LICENSURE AND CERTIFICATION

1981 Massachusetts License Registration #47934
1982 American Board of Pediatrics
1984 California License #G52364

ACADEMIC APPOINTMENTS

1978-1983 Fellow in Pediatrics, Harvard Medical School, Boston, MA
1983-1984 Instructor in Pediatrics, Harvard Medical School, Boston, MA
1984-1989 Assistant Professor of Pediatrics, Stanford University, Stanford, CA

1989-1994 Associate Professor of Pediatrics, Stanford University, Stanford, CA
 1991-1992 Acting Chief, Division of Nephrology, Department of Pediatrics, Stanford University, Stanford, CA
 1994- Professor of Pediatrics, Stanford University, Stanford, CA
 1995- Shelagh Galligan Professor of Pediatrics, Stanford University, Stanford, CA
 1995- Chief, Division of Immunology and Transplantation Biology, Department of Pediatrics, Stanford University, Stanford, CA
 1997-1998 Acting Chief, Division of Nephrology, Department of Pediatrics, Stanford University, Stanford, CA
 1999- Associate Chair for Research, Department of Pediatrics, Stanford University, Stanford, CA
 1999- Associate Dean for Children's Health, Stanford University School of Medicine, Stanford, CA

MEDICAL SCHOOL, UNIVERSITY COMMITTEES AND APPOINTMENTS

1984-1986 Director, Stanford Seminars in Immunology
 1985 Organizer, Asilomar Immunology Retreat
 1985-1989 Medical Scientist Training Program (MSTP) Committee
 1988-1991 Program in Cancer Biology Committee
 1989-1992 Program in Molecular and Genetic Medicine Steering Committee
 1989-1992 Program in Immunology Fellowship Selection Committee
 1990- Program in Immunology Executive Committee
 1991-1993 University Committee on Graduate Studies
 1992-1996 Program in Immunology Pre-doctoral Committee
 1993-1994 University Administrative Panel on Human Subjects in Non-Medical Research
 1993-1994 University Task Force to Review Administrative Panels
 1994- Executive Committee, Integrated Program in Clinical Immunology
 1994-1997 Chairman, Integrated Program in Clinical Immunology Transplantation Sub-committee
 1995- Chief, Division of Immunology and Transplantation Biology, Department of Pediatrics
 1995-1999 Medical School Faculty Senate
 1996-1999 Medical School Appointments and Promotions Committee
 1996- Children's Health Research Center Steering Committee
 1996-1998 Medical School Bench to Bedside (Interdisciplinary Center Development) Committee
 1997-1998 Medical School Space Utilization Committee
 1999-2000 UCSF-Stanford Interschool Academic Council
 1999- Associate Chair for Research, Department of Pediatrics
 1999- Associate Dean for Children's Health, Stanford University School of Medicine
 2000- Executive Director, Children's Health Initiative, Stanford University School of Medicine and Lucile Salter Packard Children's Hospital

HOSPITAL APPOINTMENTS

1983-1984 Assistant in Medicine, Children's Hospital, Boston, MA
 1984- Attending Physician in Pediatrics and Pediatric Nephrology, Stanford University Hospital and Children's Hospital at Stanford, Stanford, CA

1991-1992	Acting Chief, Division of Pediatric Nephrology, Stanford University and Lucile Salter Packard Children's Hospital, Stanford, CA
1997-1998	Acting Chief, Division of Pediatric Nephrology, Stanford University and Lucile Salter Packard Children's Hospital, Stanford, CA
2001-	Executive Committee, Lucile Salter Packard Children's Hospital, Stanford, CA

AWARDS AND HONORS

1972	Alpha Epsilon Delta
1973	Phi Beta Kappa
1977	Alpha Omega Alpha
1977	Marie Lebron Prize in Pediatrics
1977	Morton McCutcheon Memorial Prize
1977	Merck Award
1983-1988	American Heart Association Clinician - Scientist Award
1983	Medical Foundation Fellowship
1983-1985	Joseph A. Shankman Award of National Kidney Foundation of MA
1984-1987	Basil O'Connor Award (March of Dimes)
1984	Mellon Foundation Fellowship
1985	Society for Pediatric Research Young Investigator Award
1985	American Society for Histocompatibility and Immunogenetics Young Investigator Award
1988-1993	American Heart Association - Established Investigator Award
1990	American Society of Nephrology Young Investigator Award
1993	American Academy of Pediatrics Award for Excellence in Research
1994	David Cornfeld Lecture, Children's Hospital of Philadelphia
1994-1999	Burroughs Wellcome Scholar in Experimental Therapeutics
1994	American Society of Clinical Investigation
1995	E. Mead Johnson Award for Research in Pediatrics
1996	David Hume Lecture, American Society of Transplant Physicians
1999	Novartis Established Investigator Award of the American Society of Transplantation
2000	Roche Visiting Professor, Harvard Medical School and Children's Hospital Medical Center, Boston
2002	American Pediatric Society
2002	Robert Haslam Lecture, The Hospital for Sick Children, Toronto, Canada
2002	Association of American Physicians
2002	John Kapp Clark Lecture, University of Pennsylvania

EDITORIAL APPOINTMENTS

1987-1991	Associate Editor, Journal of Immunology
1989-1991	Section Editor, Current Opinion in Pediatrics
1996-1999	Editorial Board, Pediatric Nephrology
1996-2001	Associate Editor, Journal of the American Society of Nephrology
1997-	Editorial Board, Pediatric Transplantation
1997-	Assistant Editor for Transplantation and Immunology, Pediatric Nephrology
1998-2001	Editorial Board, Graft
2004-2007	Editorial Board, Annual Review of Medicine

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES

American Society of Nephrology
 American Society of Pediatric Nephrology
 American Association of Immunologists
 The Transplantation Society
 Society for Pediatric Research
 American Society of Clinical Investigation
 International Society of Nephrology
 American Society of Transplant Physicians
 American Association of Clinical Immunology
 American Pediatric Society
 Association of American Physicians

1988	NIH Immunological Science Study Section, ad hoc reviewer
1988	SPR Subspeciality Chairperson (Nephrology)
1989	NIH NIA Review of the Laboratory of Clinical Physiology - Immunology (Aging Institute)
1989	NIH Immunobiology Study Section, ad hoc reviewer
1990	NIH Experimental Immunology Study Section, ad hoc reviewer
1990-1991	American Heart Association (CA) Research Peer Review Subcommittee
1991-1995	NIH Experimental Immunology Study Section, member
1991-1992	NIH Experimental Immunology Workshop Steering Committee
1991-1992	American Society of Nephrology Program Committee Co-Chairperson (Immunology & Transplantation) for Annual Meeting
1991-1995	American Society of Nephrology Membership and Award Committee
1991-1994	American Society of Nephrology Workshop/Basic Science Committee
1992-1995	American Association of Immunologists Membership Committee
1993-1995	Chairman, NIH Experimental Immunology Study Section
1993-1994	American Heart Association Natl. Peer Review Group
1993-1996	American Society of Nephrology Research Priorities Committee
1994-1995	Host Committee, 1995 International Congress of Immunology
1994-1998	Medical Advisory Board, National Kidney Foundation of Northern California
1994-1997	Society for Pediatric Research Young Investigator Award Committee
1995	NIH Expert Panel on Transplantation Tolerance
1995	Chairman, American Society of Nephrology Young Investigator Award Committee
1995-1998	Council, Society for Pediatric Research (Nephrology)
1995	NIH NIA Review of the Laboratory of Clinical Physiology - Immunology (Aging Institute) - ad hoc member
1995-1999	American Society of Pediatric Nephrology Research Committee
1995-1997	Chairman, Society for Pediatric Research Young Investigator Award Committee
1996-1999	American Cancer Society Institutional Review Group
1998	NIH - NIAID Council, ad hoc member
1998-2001	American Society of Transplantation Awards Committee
1999-2001	American Society of Transplantation Basic Science Committee
1999-2002	American Society of Nephrology Transplant Advisory Group
1999-2000	Vice President, Society for Pediatric Research
1999-	Steering Committee, Immune Tolerance Network (NIAID, NIDDK, JDFI)
1999-	Scientific Review Committee, Immune Tolerance Network (NIAID, NIDDK, JDFI)

1999-2002	Pediatric Academic Societies Program Committee
2000-2001	President-elect, Society for Pediatric Research
2000-2001	Pediatric Academic Societies-American Academy of Pediatrics Subcommittee on Future Participants
2000-2001	Member, Federation of Pediatric Organizations (FOPO)
2000-2003	Member, E. Mead Johnson Award Committee
2001-2002	President, Society for Pediatric Research
2001-2005	Burroughs Wellcome Fund Translational Research Advisory Committee
2002-2003	Past-President, Society for Pediatric Research
2002-	Member, Association of American Physicians
2002	Secretary-Treasurer elect of American Society of Nephrology
2003-2006	Secretary-Treasurer of American Society of Nephrology
2003-2006	Chair of Awards Committee, American Society of Nephrology
2003-2006	Finance Committee, American Society of Nephrology
2003-2006	Publications Committee, American Society of Nephrology

PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES

1983-1984	Attending physician, Renal Service, Children's Hospital, Boston, MA
1983-1984	Attending physician, Medical Intensive Care Unit, Children's Hospital, Boston, MA
1984-1994	Attending physician, Pediatric Nephrology Service, Stanford University Medical Center, Stanford, CA
1985-	Attending physician, Pediatrics, Stanford University Medical Center, Stanford, CA
1991-1992	Acting Chief, Division of Pediatric Nephrology, Stanford University and Lucile Salter Packard Children's Hospital, Stanford, CA
1997-1998	Acting Chief, Division of Pediatric Nephrology, Stanford University and Lucile Salter Packard Children's Hospital, Stanford, CA

TEACHING EXPERIENCE

1981-1984	Visiting Lecturer in Pathophysiology, Massachusetts College of Pharmacy, Boston, MA
1983-1984	Lecturer, Graduate Immunology Course, Harvard University, Boston, MA
1984-1999	Lecturer, Immunology Course (Med Micro 200, Path 220), Stanford University Medical School, Stanford, CA
1984-1994	Attending Physician, Pediatrics 306A, Pediatric Nephrology Clerkship, Stanford
1985-1999	Lecturer, Advanced Immunology Course (Med Micro 202), Stanford
1985-	Advisor, Pediatrics 399, Research, Stanford
1985-	Attending Physician, Pediatrics 300A, Child Health Clerkship, Stanford
1986-1987	Lecturer, Interdepartmental 241, Molecular and Cellular Aspects of Cancer Biology, Stanford
1986-	Advisor, Biology 199, Special Problems in Biology, Stanford

MAJOR RESEARCH INTERESTS

Human Cellular and Molecular Immunology
Transplantation Immunobiology
Tumor Immunobiology

PUBLICATIONS

1. Krensky AM, Bongiovanni AM, Marino J, Parks J, Tenore A: Identification of heterozygote carriers of congenital adrenal hyperplasia by radioimmunoassay of serum 17-OH progesterone. *J. Pediatr.* 1977; 90: 930-933.
2. Krensky AM, Berenberg W, Shanley K, Yunis EJ: HLA antigens in mucocutaneous lymph node syndrome in New England. *Pediatrics* 1981; 67: 741-3.
3. Krensky AM, Harmon WE, Ingelfinger JR, Kirkpatrick JR, Grupe WE: Elevated nephrogenous cyclic adenosine monophosphate to monitor early renal osteodystrophy. *Clin. Nephrology* 1981; 16: 245-250.
4. Krensky AM, Grupe WE, Harmon WE, Ingelfinger JR: Elevation of nephrogenous cyclic adenosine monophosphate as evidence of early renal osteodystrophy. In: *Renal Insufficiency in Children*. Ed., M Bulla. Springer-Verlag, Berlin, 1982; pp. 86-91.
5. Krensky AM, Ingelfinger JR, Grupe WE: Peritonitis in childhood nephrotic syndrome. *Am. J Dis. Child* 1982; 136: 732-736.
6. Krensky AM: Technique for infrequent arterial blood gas monitoring in the newborn. *Clin. Pediatr. (Phila)*. 1982; 21: 57.
7. Leung DYM, Siegel RL, Grady S, Krensky AM, Meade R, Reinherz EL, Geha RS: Immunoregulatory abnormalities in mucocutaneous lymph node syndrome. *J. Clin. Immunol. Immunopath.* 1982; 23: 100-112.
8. Krensky AM, Reiss CS, Mier JW, Strominger JL, Burakoff SJ: Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. *Proc. Natl. Acad. Sci. USA* 1982; 79: 2365-2369.
9. Krensky AM, Ault KA, Reiss CS, Strominger JL, and Burakoff SJ: Generation of long-term human cytolytic cell lines with persistent natural killer activity. *J. Immunol.* 1982; 129: 1748-1751.
10. Krensky AM, Clayberger C, Reiss CS, Strominger JL and Burakoff SJ: Specificity of OKT4+ cytotoxic T lymphocyte clones. *J. Immunol.* 1982; 129: 2001-2003.
11. Sanchez-Madrid F, Krensky AM, Ware CF, Robbins E, Strominger JL, Burakoff SJ, Springer TA: Three distinct antigens associated with human T-lymphocyte-mediated cytotoxicity: LFA-1, LFA-2, and LFA-3. *Proc. Natl. Acad. Sci. USA* 1982; 79: 7489-7493.
12. Krensky AM, Ingelfinger JR, Grupe WE, and Rosen S: Hemolytic Uremic Syndrome and Crescentic Glomerulonephritis complicating childhood nephrosis. *Clin. Nephrology* 1983; 19: 99-106.
13. Krensky AM, Grady S, Shanley KM, Berenberg W, Yunis EJ: Epidemic and endemic HLA-B and DR associations in mucocutaneous lymph node syndrome. *Human Immunology* 1983; 6: 75-77.
14. Krensky AM, Reddish J, Teele RL: Causes of increased renal echogenicity in pediatric patients. *Pediatrics* 1983; 72: 840-846.

15. Rosen S, Harmon W, Krensky AM, Edelson PJ, Padgett BL, Grinnell BW, Rubino MS, Walker DL: Tubulo-interstitial nephritis associated with polyomavirus (BK type) infection. *N. Engl. J. Med.* 1983; 308: 1192-1196.
16. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy J, Springer TA, Burakoff SJ: The functional significance, distribution and structure of LFA-1, LFA-2, and LFA-3: Cell surface antigens associated with the CTL-target interactions. *J. Immunol.* 1983; 131: 611-616.
17. Ware CF, Sanchez-Madrid F, Krensky AM, Burakoff SJ, Strominger JL, and Springer TA: Human lymphocyte function associated antigen-1 (LFA-1): Identification of multiple antigenic epitopes and their relationship to CTL-mediated cytotoxicity. *J. Immunol.* 1983; 131: 1182-1188.
18. Pober JS, Collins T, Gimbrone MA, Cotran RS, Gitlin J, Fiers W, Clayberger C, Krensky AM, Burakoff SJ, Reiss CS: Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. *Nature* 1983; 305: 726-729.
19. Krensky AM, Clayberger C, Greenstein J, Crimmins M, Burakoff SJ: A DC specific cytolytic T lymphocyte line is OKT8+. *J. Immunol.* 1983; 131: 2777-2780.
20. Krensky AM, Burakoff SJ: Basic Science Seminar: Cytotoxic T-lymphocyte response to HLA antigens. *J. Pediatr.* 1983; 102: 814-819.
21. Burakoff SJ, Clayberger C, Hemler M, Krensky AM, Reiss CS, Robbins E, Sanchez-Madrid F, Springer TA, Strominger JL, Ware CF: Cytotoxic T cells directed against HLA-DR antigens and their surface proteins. *Diag. Immunol.* 1983; 1: 116-119.
22. Hemler ME, Sanchez-Madrid F, Flotte TJ, Krensky AM, Burakoff SJ, Bhan AK, Springer TA, and Strominger JL: Glycoproteins of 210,000 and 130,000 M.W. on activated T cells: Cell distribution and antigenic relation to components on resting cells and T cell lines. *J. Immunol.* 1984; 132: 3011-3018.
23. Krensky AM, Sanchez-Madrid F, Springer TA, and Burakoff SJ: Human lymphocyte function associated antigens. *Survey of Immunological Research.* 1984; 3: 39-44.
24. Greenberger JS, Sakakeeny MA, Krensky AM, Burakoff S, Reid D, Novak T, and Boggs SS: Experimental evidence for the potential usefulness of permanent IL-3 dependent multipotential hematopoietic progenitor cell lines in transfusion granulocyte support therapy: Need for expansion of early passage cells. In: *Long-term Bone Marrow Culture.* Ed., DG Wright, JS Greenberger. Alan R. Liss, Inc., New York, 1984; pp. 255-273.
25. Krensky AM, Robbins E, Springer TA, and Burakoff SJ: LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation. *J. Immunol.* 1984; 132: 2180-2182.
26. Greenberger JS, Krensky AM, Messner H, Burakoff SJ, Wandt U, Sakakenny MA: Production of colony stimulating factor(s) for granulocyte-macrophage and multipotential granulocyte/erythroid/megakaryocyte/macrophage hematopoietic progenitor cells (CFU-GEMM) by clonal lines of human IL-2 dependent T lymphocytes. *Exp. Hematology.* 1984; 12: 720-727.

27. Collins T, Krensky AM, Clayberger C, Fiers W, Gimbrone MA, Burakoff SJ, Pober JS: Human cytolytic T lymphocyte interactions with vascular endothelium and fibroblasts: Role of effector and target cell molecules. *J. Immunol.* 1984; 133: 1878-1884.
28. Burakoff SJ, Weinberger O, Krensky AM, and Reiss CS: A molecular analysis of the cytolytic T lymphocyte response. In: *Advances in Immunology*, Vol 36. Ed., FJ Dixon. Academic Press, Inc., Orlando, 1984; pp. 45-85.
29. Pober JS, Gimbrone MA, Collins T, Cotran RS, Ault KA, Fiers W, Krensky AM, Clayberger C, Reiss CS, Burakoff SJ: Interaction of T lymphocytes with human vascular endothelial cells: Role of endothelial cells surface antigens. *Immunobiol.* 1984; 168: 483-494.
30. Krensky AM, Clayberger C, Greenstein JL, Collins T, Pober JS, Robbins E, Anderson D, Springer TA, Burakoff SJ: Cell surface structures involved in the human cytolytic T lymphocyte response. In: *Regulation of the Immune System*. Ed., H Cantor, L Chess, E Secarz. Alan R. Liss, Inc., New York, 1984; pp. 209-219.
31. Krensky AM, Mentzer S, Greenstein JL, Crimmins M, Clayberger C, Springer TA, Burakoff SJ: Human cytolytic T-lymphocyte clones and function-associated cell surface molecules. In: *Hybridomas in Biotechnology and Medicine*. Ed., TA Springer. Plenum Press, New York, 1985; pp. 559-574.
32. Gromkowski SH, Krensky AM, Martz E, Burakoff SJ: Functional distinctions between the LFA-1, LFA-2, and LFA-3 membrane proteins on human CTL are revealed with trypsin-pretreated target cells. *J. Immunol.* 1985; 134: 244-249.
33. O'Flynn K, Krensky AM, Beverly PCL, Burakoff SJ, and Linch DS: Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor. *Nature* 1985; 313: 686-687.
34. Mentzer SJ, Gromkowski SH, Krensky AM, Burakoff SJ, Martz E: LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytes. *J. Immunol.* 1985; 135: 9-11.
35. Mentzer SJ, Barbosa JA, Krensky AM, Biro PA, Strominger JL, Burakoff SJ: Species-specific cytotoxic T lymphocyte recognition of major histocompatibility antigens HLA-A2 and HLA-B7 after DNA-mediated gene transfer. *Transpl. Proc.* 1985; 27: 969-971.
36. Springer TA, Rothlein R, Anderson DC, Burakoff SJ, and Krensky AM: The function of LFA-1 in cell-mediated killing and adhesion: Studies on heritable LFA-1, Mac-1 deficiency and on lymphoid cell self-aggregation. In: *Advances in Experimental Medicine and Biology*, vol. 184. *Mechanisms of Cell Mediated Cytotoxicity II*. Ed., P Henkart, E Martz. Plenum Press, New York, 1985; pp. 311-320.
37. Mentzer S, Greenstein JL, Krensky AM, Burakoff SJ: Cell surface antigens involved in human cytolytic T lymphocyte-mediated cytolysis. In: *Human T cell clones*. Ed., M Feldman, JR Lamb, JN Woody. Humana Press, Clifton, NJ, 1985; pp. 187-196.
38. Krensky AM, Clayberger C: Diagnostic and therapeutic implications of T cell surface antigens. *Transplantation*. 1985; 39: 339-348.

39. Clayberger C, Uyehara T, Hardy B, Eaton J, Karasek M, Krensky AM: Target specificity and cell surface structures involved in the human cytolytic T lymphocyte response to endothelial cells. *J. Immunol.* 1985; 135: 12-18.
40. Navarro RF, Jalkanen ST, Hsu M, Soenderstrup-Hansen G, Goronzy J, Weyand C, Fathman CG, Clayberger C, Krensky AM, Butcher EC: Human T cell clones express functional homing receptors required for normal lymphocyte trafficking. *J. Exp. Med.* 1985; 162: 1075-1080.
41. Krensky AM: The human cytolytic T lymphocyte response to transplantation antigens. Transcript of the third annual Society for Pediatric Research Young Investigator Award presentation. *Pediatr. Res.* 1985; 19: 1231-1234.
42. Krensky AM, Lanier LL, Engleman EG: Lymphocyte subsets and surface molecules in man. *Clinical Immunology Reviews.* 1985; 4: 95-138.
43. Krensky AM, Mentzer SJ, Clayberger C, Anderson CD, Schmalstieg FC, Burakoff SJ, Springer TA: Heritable lymphocyte function-associated antigen-1 deficiency: Abnormalities of cytotoxicity and proliferation associated with abnormal expression of LFA-1. *J. Immunol.* 1985; 135: 3102-3108.
44. Clayberger C, Holmes N, Wang PL, Koller TD, Parham P, Krensky AM: Determinants recognized by human cytotoxic T cells on a natural hybrid Class I HLA molecule. *J. Exp. Med.* 1985; 162: 1709-1714.
45. Krensky AM, Clayberger C: MHC-unrestricted cytolytic T lymphocytes. *Survey of Immunological Research.* 1985; 4: 297-302.
46. Clayberger C, Dyer B, McIntyre B, Koller TD, Hardy B, Parham P, Lanier LL, Krensky AM: Function and cell distribution of KC-1, a novel natural killer cell-associated antigen. *J. Immunol.* 1986; 136: 1537-1541.
47. Mentzer S, Krensky AM, Burakoff SJ: Mapping functional epitopes of the human LFA-1 glycoprotein: Monoclonal antibody inhibition of NK and CTL effectors. *Human Immunology* 1986; 17: 288-296.
48. Kahn MM, Keaney KM, Krensky AM, Melmon KL: The modulation of generation/function of human cytotoxic lymphocytes by autotoxins: Unusually compartmentalized cAMP? *Proc. West Pharmacol. Soc.* 1986; 29: 31-34.
49. Krensky AM, Tune BM: Diseases of the kidney in the fetus and neonate. In: *Prenatal and Perinatal Biology and Medicine.* Eds., N Kretchmer, T Quilligan, J Johnson. Harwood Academic Publishers, Switzerland. 1987; pp. 303-348.
50. Parham P, Clayberger C, Zorn SL, Ludwig DS, Schoolnik GK, Krensky AM: Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha2 domain of HLA-A2. *Nature.* 1987; 325: 625-628.
51. Clayberger C, Krensky AM, McIntyre BW, Koller TD, Parham P, Brodsky F, Linn DJ, Evans EL: Identification and characterization of two novel lymphocyte function-associated antigens, L24 and L25. *J. Immunol.* 1987; 138: 1510-1514.
52. Mendoza FS, Atiba JO, Krensky AM, Scannell LM: Rhabdomyolysis complicating doxylamine overdose. *Clin. Pediatrics.* 1987; 26: 595-597.

53. Koller TD, Clayberger C, Maryanski JL, Krensky AM: Human allospecific cytolytic T lymphocyte lysis of a murine cell transfected with HLA-A2. *J. Immunol.* 1987; 138: 2044-2049.
54. Lanier LL, Le AM, Ding A, Evans EL, Krensky AM, Clayberger C, Phillips, JH: Expression of Leu 19 (NKH-1) antigen on IL 2-dependent cytotoxic and non-cytotoxic T cell lines. *J. Immunol.* 1987; 138: 2019-2023.
55. Jongstra J, Schall TJ, Dyer BJ, Clayberger C, Jorgensen J, Davis MM, Krensky AM: The isolation and sequence of a novel gene from a human functional T cell line. *J. Exp. Med.* 1987; 165: 601-614.
56. Salter RD, Clayberger C, Lomen CE, Krensky AM, Parham P: In vitro mutagenesis at a single residue introduces B and T cell epitopes into a Class I HLA molecule. *J. Exp. Med.* 1987; 166: 283-288.
57. Clayberger C, Wright A, Medeiros LJ, Koller TD, Link MP, Smith SD, Warnke RA, Krensky AM: Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. *Lancet.* 1987; ii: 533-536.
58. Clayberger C, Parham P, Rothbard J, Ludwig DS, Schoolnik GK, Krensky AM: HLA-A2 peptides can regulate cytotoxicity by human allogeneic T lymphocytes. *Nature.* 1987; 330: 763-765.
59. Nickoloff BJ, Lewinsohn DM, Butcher EC, Krensky AM, Clayberger C: Recombinant gamma interferon increases the binding of peripheral blood mononuclear leukocytes and a Leu-3+T lymphocyte clone to cultured keratinocytes and to a malignant cutaneous squamous carcinoma cell line that is blocked by antibody against the LFA-1 molecule. *J. Invest. Derm.* 1988; 90: 17-22.
60. Krensky AM, Landers DV, Clayberger C: Interaction of cytolytic T-lymphocytes with endothelium. In: *Nephrology Vol I.* Davison AM, ed. Bailliere Tindell, London, 1988; pp. 365-374.
61. Seong RH, Clayberger CA, Krensky AM, Parnes JR: Rescue of Daudi cell HLA expression by transfection of the mouse beta2-microglobulin gene. *J. Exp. Med.* 1988; 167: 288-299.
62. Krensky AM, Parham P, Rothbard J, Ludwig DS, Schoolnik GK, Clayberger C: Peptides derived from HLA-A2 modulate lysis by HLA-A2-specific cytotoxic T lymphocytes. In: *Immunobiology of HLA. Vol 2: Immunogenetics and Histocompatibility.* Ed., B. Dupont. Springer-Verlag, New York, 1988, pp. 35-37.
63. Salter RD, Clayberger C, Lomen CE, Krensky AM, Parham P: Cytotoxic T cell and antibody recognition of HLA-A2, A28 molecules analyzed by site directed mutagenesis. In: *Immunobiology of HLA. Vol 2: Immunogenetics and Histocompatibility.* Ed., B. Dupont. Springer-Verlag, New York, 1988, pp. 33-34.
64. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM: A human T cell-specific molecule is a member of a new gene family. *J. Immunol.* 1988; 141: 1018-1025.

65. Hogan KT, Clayberger C, Le AT, Walk SF, Ridge JP, Parham P, Krensky AM, Engelhard VH: Cytotoxic T lymphocyte-defined epitope differences between HLA-A2.1 and HLA-A2.2 map to distinct regions of the molecule. *J. Immunol.* 1988; 141: 4005-4011.
66. Hogan KT, Clayberger C, Bernhard EJ, Walk SF, Ridge JP, Parham P, Krensky AM, and Engelhard VH: Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3. *J. Immunol.* 1988; 141: 2519-2525.
67. Medeiros LJ, Weiss LM, Picker LJ, Clayberger C, Horning SJ, Krensky AM, and Warnke RA: Expression of LFA-1 in Non-Hodgkin's lymphoma. *Cancer.* 1989; 63: 255-259.
68. Hogan KT, Clayberger C, Bernhard EJ, Walk SF, Ridge JP, Parham P, Krensky AM, and Engelhard VH: A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes. *J. Immunol.* 1989; 142: 2097-2104.
69. Khan MM, Keaney KM, Melmon KL, Clayberger C, and Krensky AM: Histamine regulates the generation of human cytolytic T lymphocytes. *Cell. Immunol.* 1989; 121: 60-73.
70. Wright A, Lee JE, Link MP, Smith SD, Carroll W, Levy R, Clayberger C, and Krensky AM: Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain. *J. Exp. Med.* 1989; 169: 1557-1564.
71. Krensky AM, Clayberger C: The molecular basis of renal transplant rejection. *Seminars in Nephrology.* 1989; 9: 116-119.
72. Bishop GA, Waugh JA, Landers DV, Krensky AM, and Hall BM: Microvascular destruction in renal transplant rejection. *Transplantation.* 1989; 48: 408-414.
73. Salter RD, Norment AM, Chen BP, Clayberger C, Krensky AM, Littman DR, and Parham P: Polymorphism in the alpha3 domain of HLA-A molecules affects binding to CD8. *Nature.* 1989; 338: 345-347.
74. Parham P, Benjamin RJ, Chen BP, Clayberger C, Ennis PD, Krensky AM, Lawlor DA, Littman DR, Norment AM, Orr HT, Salter RD, Zemmour J: Functional diversity of class I HLA molecules. *Cold Spring Harbor Symposium on Quantitative Biology, Volume LIV,* 1989; pp. 529-543.
75. Krensky AM, Suranyi MG, Clayberger C, Hall BM: Advances in the immunobiology and clinical practice of transplantation. *Current Nephrology, vol 13.,* HC Gonick, ed. Yearbook Medical Publishers, 1990; pp. 417-465.
76. Krensky AM, Weiss A, Crabtree G, Davis M, Parham P: Mechanisms of disease: T lymphocyte - antigen interactions in transplant rejection. *N. Engl. J. Med.* 1990; 322: 510-517.
77. Donlon TA, Krensky AM, Wallace MR, Collins FS, Lovett M, and Clayberger C: Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2-q12. *Genomics.* 1990; 6: 548-553.

78. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM: Successful treatment of childhood steroid-resistant nephrotic syndrome due to focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents. *Pediatr. Nephrol.* 1990; 4: 303-307.
79. Clayberger C, Rosen M, Parham P, Krensky A: Recognition of an HLA public determinant (Bw4) by human allogeneic cytotoxic T lymphocytes. *J. Immunol.* 1990; 144: 4172-4176.
80. Donlon TA, Krensky AM, Clayberger C: Localization of the human T lymphocyte activation gene 519 (D2S69E) to chromosome 2p12-q11. *Cytogenet. Cell Genet.* 1990; 53: 230-231.
81. Krensky AM: Kidneys and Urinary Tract. Editorial Overview. *Curr. Opin. Pediatr.* 1990; 2: 325-326.
82. Yorgin PD, Krensky AM: Renal Transplantation. *Curr. Opin. Pediatr.* 1990; 2: 351-358.
83. Kadiyala RK, McIntyre BM, Krensky, AM: Molecular cloning and characterization of WP34, a phosphorylated human lymphocyte differentiation and activation antigen. *Eur. J. Immunol.* 1990; 20: 2417-2423.
84. Salter RD, Benjamin RJ, Wesley PK, Buxton S, Garrett TPJ, Clayberger C, Krensky AM, Norment AM, Littman DR, Parham P: A binding site for the T cell co-receptor, CD8, on the alpha3 domain of HLA-A2. *Nature.* 1990; 345: 41-46.
85. Suranyi MG, Bishop GA, Clayberger C, Krensky AM, Leenaerts P, Hall BM: The importance of the ICAM-1/LFA-1 dependent pathway in in-vitro cytotoxicity against cultured human kidney cells. *Transplant. Proceed.* 1990; 22: 2101-2102.
86. Yorgin PD, Krensky AM, Tune BM. Continuous venovenous hemofiltration. *Pediatr. Nephrol.* 1990; 4: 640-642.
87. Hogan KT, Clayberger C, Krensky AM, Engelhard VH: The role of amino acid position and side chain structure in serological and CTL-defined epitopes on the HLA-A2.1 molecule. In *Transgenic Mice and Mutants in MHC Research*. Egorov I. and David CS, eds. Springer-Verlag, Berlin. 1990; pp. 77-88.
88. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM: Treatment of childhood steroid-resistant focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents. In: *Proceedings of the XIth International Congress of Nephrology, volume II*. M. Hatano (Ed.). Springer-Verlag, Tokyo, 1991, pp 1480-1485.
89. Suranyi MG, Bishop GA, Clayberger C, Krensky AM, Leenaerts P, Aversa G, Hall BM: Lymphocyte adhesion molecules in T cell mediated lysis of human kidney cells. *Kidn. Intl.* 1991; 39: 312-319.
90. Krensky AM: Molecular basis of transplant rejection and acceptance. *Pediatr. Nephrol.* 1991; 5: 422-427.
91. Krensky AM: Kidneys and urinary tract. Editorial Overview. *Curr. Opin. Pediatr.* 1991; 3: 248-249.

92. Devaux B, Bjorkman PJ, Stevenson C, Greif W, Elliot JF, Sagerstrom C, Clayberger C, Krensky AM, Davis MM: Generation of monoclonal antibodies against soluble human T cell receptor polypeptides. *Eur. J. Immunol.* 1991; 21: 2111-2119.
93. Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Levy R, Krensky AM: Interleukin-3 is a growth factor for human follicular B cell lymphoma. *J. Exp. Med.* 1992; 175: 371-376.
94. Buxton SE, Benjamin RJ, Clayberger C, Parham P, Krensky AM: Anchoring pockets in HLA class I molecules: Analysis of the conserved B ("45") pocket of HLA-B27. *J. Exp. Med.* 1992; 175: 809-820.
95. Heeger P, Wolf G, Meyers C, Sun MJ, O'Farrell S, Krensky AM, Neilson EG: Isolation and characterization of cDNA from renal tubular epithelium encoding the murine RANTES, a small intercrine from the Scy superfamily. *Kidn. Intl.* 1992; 41: 220-225.
96. Wang PL, O'Farrell S, Clayberger C, Krensky AM: Identification and molecular cloning of Tactile: A novel human T cell activation antigen that is a member of the immunoglobulin gene superfamily. *J. Immunol.* 1992; 148: 2600-2608.
97. Luna-Fineman S, Lee JE, Wesley PK, Clayberger C, Krensky AM: Human cytotoxic T lymphocytes specific for autologous follicular lymphoma recognize immunoglobulin in an MHC restricted fashion. *Cancer* 1992; 70: 2181-2186.
98. Ozen S, Clayberger C, Krensky AM, Benjamin R: Effects of the substitution of critical residues on the allorecognition of HLA-B27. *Clin. Exper. Rheumatol.* 1992; 10: 583-587.
99. Manning WC, O'Farrell S, Goralski TJ, Krensky AM: Genomic structure and alternative splicing of 519, a gene expressed late after T cell activation. *J. Immunol.* 1992; 148: 4036-4042.
100. Wesley PK, Clayberger C, Lyu S-c, Krensky AM: The CD8 coreceptor interaction with the alpha 3 domain of HLA class I is critical to the differentiation of human cytotoxic T-lymphocytes specific for HLA-A2 and HLA-Cw4. *Hum. Immunol.* 1993; 36: 149-155.
101. Krensky AM: Transplantation Immunobiology, In: Holliday MA, Barratt TM & Avner ED, eds. *Pediatric Nephrology*, 3rd Ed, Williams and Wilkins, Baltimore, 1993, pp. 1373-1389.
102. Lee D-Y, Cohen P, Krensky AM, Rosenfeld RG, Yorgin PD: Insulin-like growth factor binding protein-3 (IGFBP-3) protease activity in the urine of children with chronic renal failure. *Pediatric Nephrology.* 1993; 7: 416-423.
103. Krensky AM, Lyu S-c, Pouletty P, Benjamin R, Parham P, Clayberger C: Peptides corresponding to the CD8 binding region of HLA class I block the differentiation of cytotoxic T lymphocyte precursors. *Transpl. Proc.* 1993; 25: 483-4.
104. Clayberger C, Lyu S-c, Pouletty P, Krensky AM: Peptides corresponding to T cell receptor - HLA contact regions inhibit class I restricted immune responses. *Transpl. Proc.* 1993; 25: 477-8.
105. Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM: Genomic organization and transcriptional regulation of the RANTES chemokine gene. *J. Immunol.* 1993; 151: 2601-12.

106. Wolf G, Aberle S, Thaiss F, Nelson PJ, Krensky AM, Neilson EG, Stahl RAK: TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. *Kidn. Intl.* 1993; 44: 795-804.
107. Wiedermann CJ, Kowald E, Reinisch N, Kahler CM, von Luetlichau I, Nelson PJ, Krensky AM: Monocyte haptotaxis induced by RANTES chemokine. *Curr Biol.* 1993; 3: 735-739.
108. Krensky AM, Clayberger C: The nature of allorecognition. *Current Opin. Nephrol. Hyperten.* 1993; 2: 898-903.
109. Krensky AM: T cells in autoimmunity and allograft rejection. *Kidn. Intl.* 1994; 45: S50-S56.
110. Pattison J, Nelson PJ, Huie P, von Luetlichau I, Farshid G, Sibley RK, Krensky AM: RANTES chemokine is highly expressed in cell mediated transplant rejection of the kidney. *Lancet.* 1994; 343: 209-211.
111. Nisco S, Vriens P, Hoyt G, Lyu S-c, Farfan F, Pouletty P, Krensky AM, Clayberger C: Induction of allograft tolerance in rats by an HLA class I derived peptide and cyclosporine A. *J. Immunol.* 1994; 152: 3786-3792.
112. Clayberger C, Lyu S-c, DeKruyff R, Parham P, Krensky AM: Peptides corresponding to the CD8 and CD4 binding domains of HLA molecules block T lymphocyte immune responses in vitro. *J. Immunol.* 1994; 153: 946-951.
113. Krensky AM, Clayberger C: Transplantation Immunology. *Ped Clin NA.* 1994; 41: 819-839.
114. Krensky AM, Clayberger C: The induction of tolerance to alloantigens using HLA based synthetic peptides. *Curr. Opin. Immunol.* 1994; 6: 791-796.
115. Krensky AM, Clayberger C: Prospects for induction of tolerance in renal transplantation. *Pediatr. Nephrol.* 1994; 8: 772-779.
116. Wang PL, Krensky AM. "Overview of Tactile/CD96" in Schlossman SF, *et al.*, eds. 1994. *Leucocyte Typing V: White Cell Differentiation Antigens*. Oxford University Press, Oxford. Vol. I, pp. 1149-1150.
117. Krensky AM, Buelow R, Clayberger C: HLA class I derived peptides as novel immunosuppressives. In Salomon DR, ed. *Recent Developments in Transplantation Medicine II - Adhesion molecules, fusion proteins, novel peptides, and monoclonal antibodies*, Physicians and Scientists Publishing Co., Inc. 1995. pp.1-12.
118. Nelson EL, Kim HT, Mar N, Goralski TJ, McIntyre BW, Clayberger C, Krensky AM: Novel tumor associated accessory molecules involved in the $\gamma\delta$ cytotoxic T lymphocyte-Burkitt's lymphoma interaction. *Cancer* 1995; 75: 886-893.
119. Kim HT, Nelson EL, Clayberger C, Sanjanwala M, Sklar J, Krensky AM: $\gamma\delta$ T cell recognition of tumor immunoglobulin peptide. *J. Immunol.* 1995; 154: 1614-1623.

120. Krensky AM, Clayberger C: HLA derived peptides as novel immunosuppressives. *Proc. Assoc. Am. Phys.* 1995; 107: 81-85.
121. Pattison J, Nelson PJ, Krensky AM: The RANTES chemokine: A new target for immunomodulatory therapy? *Clinical Immunotherapeutics.* 1995; 4: 1-8.
122. Krensky AM and Clayberger C: HLA derived peptides as novel immunotherapeutics. *Clin. Immunol. Immunopath.* 1995; 75: 112-116.
123. Krensky AM, ed. *Biology of the chemokine RANTES*, Springer-Verlag, New York. 1995.
124. Krensky AM: HLA derived peptides as novel immunosuppressives. *Ped. Res.* 1995; 38: 275-279.
125. Clayberger C, Krensky AM: Immunosuppressive peptides corresponding to MHC class I sequences. *Curr. Opin. Immunol.* 1995; 7: 644-648.
126. von Luetlichau I, Nelson PJ, Stephenson C, van de Rijn M, Huie P, Pattison JM, Warnke R, Wiedermann CJ, Stahl RAK, Sibley R, Krensky AM: RANTES chemokine expression in normal and diseased tissues and during human development. *Cytokine.* 1996; 8:89-98.
127. Nelson PJ, Ortiz BD, Pattison JM, Krensky AM: Identification of a novel enhancer sequence which directs late activation of the RANTES chemokine in T lymphocytes. *J. Immunol.* 1996; 157:1139-1148.
128. Goldberg J, Clayberger C, and Krensky AM: Tolerance induction by synthetic peptides corresponding to HLA class I sequences. In Alexander JW, Good RA, eds. *Transplantation Tolerance Induction*, Springer-Verlag, New York. 1996. pp. 121-131.
129. Sayegh MH and Krensky AM: Novel immunotherapeutic strategies using MHC derived peptides. *Kidney Intl.* 1996; 49: S13-S20.
130. Nelson PJ, Pattison JM, and Krensky AM: Biology, biochemistry, and pathophysiology of the RANTES chemokine. In Horuk R, ed. *Chemoattractant Ligands and Their Receptors*, CRC Press, Boca Raton, FL, 1996. pp. 145-168.
131. Xia M, Leppert D, Hauser SL, Sreedharan SP, Nelson P, Krensky A, and Goetzl EJ: Stimulus-specificity of matrix metalloproteinase-dependence of human T cell migration through a model basement membrane. *J. Immunol.* 1996; 156: 160-7.
132. Nelson EL, Li XB, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM: Tumor specific cytotoxic T lymphocyte response after idiotype vaccination for B cell, Non-Hodgkin's lymphoma. *Blood.* 1996; 88:580-589.
133. Noessner E, Naftzger C, Clayberger C, and Krensky AM: HLA derived peptides which inhibit T cell function bind to members of the heat shock protein 70 family. *J. Exp. Med.* 1996; 183: 339-348.
134. Krensky AM, Clayberger C: Immunologic tolerance: Tailored antigen. *Transpl. Proc.* 1996; 28: 2075-2077.

135. Krensky AM, Clayberger C: Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. *Intl. Rev. Immunol.* 1996; 13: 173-185.
136. Ortiz BD, Krensky AM, Nelson PJ: Kinetics of transcription factors regulating the RANTES chemokine gene reveal a developmental switch in nuclear events during T cell maturation. *Mol. Cell. Biol.* 1996; 16: 202-210.
137. Krensky AM: Cytotoxic T lymphocyte recognition of non-Hodgkin's B cell lymphomas. *Immunol. Res.* 1996; 15: 91-97.
138. Krensky AM, Clayberger C: HLA derived peptides as a novel strategy for the prevention of allograft rejection. *Exp. Opin. Invest. Drugs.* 1996; 5: 809-18.
139. Noessner E, Krensky AM: HLA and antigen presentation. In Tilney NL, Strom TB, and Paul LC, eds. *Transplantation Biology: Cellular and Molecular Aspects*, Lippincott-Raven Press, New York, 1996. pp. 31.1-31.13.
140. Krensky AM, Clayberger C: Immunomodulation by HLA class I derived peptides. *Transpl. Proc.* 1996; 28: 3026-3028.
141. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM: RANTES chemokine expression in transplant associated atherosclerosis. *J. Heart Lung Transplant.* 1996; 15: 1194-99.
142. Pattison JM, Sibley RK, Krensky AM: Mechanisms of allograft rejection. In Neilson EG, Couser WG, eds., *Immunologic Renal Diseases*, Lippincott-Raven Publishers, Philadelphia. 1997; pp. 331-354.
143. Krensky AM: The HLA system, antigen processing and presentation. *Kidn. Intl.* 1997; 51:S2-S7.
144. Krensky AM: SCID mouse models: More than furry flasks. *Nature Biotechnology.* 1997; 15:720-721.
145. Pena SV, Hanson DA, Carr BA, Goralski TJ, Krensky AM: Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small lytic granule proteins. *J. Immunol.* 1997; 158:2680-2688.
146. Pena SV, Krensky AM: Granulysin, a new human cytolytic granule associated protein with possible involvement in cell-mediated cytotoxicity. *Sem. Immunol.* 1997; 9:117-125.
147. Nelson PJ, Pattison JM, Krensky AM: Gene expression of RANTES. In "Chemokines" *Meth. Enzymol.* 1997; 287: 148-162.
148. Krensky AM, Nelson PJ: Expression of chemokine RANTES and production of monoclonal antibodies. In "Chemokines" *Meth. Enzymol.* 1997; 287: 162-174.
149. Pattison JM, Krensky AM: New insights into mechanisms of allograft rejection. *Am. J. Med. Sci.* 1997; 313:257-263.
150. Ortiz BD, Nelson PJ, Krensky AM: Switching gears during T-cell maturation: RANTES and late transcription. *Immunology Today.* 1997; 18:468-471.

151. Krensky AM: Transplantation Immunobiology. In Jamison R and Wilkinson R, eds. Nephrology, Chapman and Hall, 1997, pp. 1051-1071.
152. Krensky AM: The biology of the chemokine RANTES. Prog. Allerg. Clin. Immunol. 1997; 4:7-11.
153. Krensky AM, Clayberger C: HLA derived peptides as novel immunosuppressives. Nephrol. Dial. Transplant. 1997; 12:865-868.
154. Krensky AM: The role of the RANTES chemokine in transplant rejection. Curr. Opin. Organ Transplant. 1997; 2:8-12.
155. Schwartz EJ, Goldberg J, Clayberger C, Krensky AM, Griffin JH: Structure-activity studies of CTL inhibitory peptides derived from HLA class I molecules. Bioorg. Med. Chem. Lett. 1997; 7:37-40.
156. Krensky AM: Immune response to allografts. In Norman DJ, Suki WN, eds., The ASTP Primer on Transplantation, American Society of Transplant Physicians, Thorofare, NJ. 1998; pp. 21-31.
157. Nelson PJ, Pattison JM, Krensky AM: The RANTES chemokine. In Mire-Sluis A and Thorpe R, eds. Cytokines, Academic Press, 1998; pp. 434-448.
158. Boytim ML, Lyu S-C, Jung R, Krensky AM, Clayberger C: Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: Functional similarities but mechanistic differences with the immunosuppressive drug rapamycin. J. Immunol. 1998; 160: 2215-2222.
159. Gamen S, Hanson DA, Naval J, Krensky AM, Anel A: Granulysin induced apoptosis. I. Involvement of at least two distinct pathways. J. Immunol. 1998; 161: 1758-1764.
160. Stenger S, Hanson DA, Teitlebaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL: An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282: 121-125.
161. Nelson PJ, Krensky AM: Chemokines, lymphocytes, and viruses: What goes around, comes around. Curr. Opin. Immunol. 1998; 10: 265-70.
162. Salvatierra O Jr., Alexander SR, Krensky AM: Pediatric kidney transplantation at Stanford. Ped. Nephrol. 1998; 2: 165-76.
163. Krensky AM, Clayberger C: The HLA-T cell interaction in transplant rejection. Graft 1998; 4: 135-141.
164. Krensky AM: Biology and therapeutic implications of the chemokine RANTES. Allergy Clin. Immunol. Intl. 1999; 11:16-21.
165. Murphy B, Krensky AM: HLA derived peptides as novel immunomodulatory therapeutics. J. Am. Soc. Nephrol. 1999; 10:1346-1355.
166. Song A, Chen Y-F, Thamatrakoln K, Krensky AM: RFLAT-1: A new zinc finger transcription factor that activates RANTES gene expression in T lymphocytes. Immunity 1999; 10: 93-103.

167. Krensky AM: Transplantation Immunobiology, In: Barratt TM, Avner ED and Harmon W, eds. Pediatric Nephrology, 4th Ed, Williams and Wilkins, Baltimore, 1999; pp. 1289-1307.
168. Clayberger C, Krensky AM: T cell immunity, In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice, 3rd Edition, Churchill Livingstone, New York, 1999; pp. 90-100.
169. Pavlakis M, Krensky AM; Immunologic principles of transplantation, In: Johnson RJ, Feehally J, eds. Principles of Nephrology, Mosby Intl, London, 1999; pp. 84.1-12.
170. Hanson DA, Kaspar AA, Poulain FR, Krensky AM: Biosynthesis of granulysin, a novel cytolytic molecule. *Molec. Immunol.* 1999; 36:413-422.
171. Stenger S, Bloom BR, Krensky AM, Modlin RL: Granulysin: a lethal weapon of cytolytic T cells. 1999. *Immunol Today* 1999; 20: 390-394.
172. Neylan JF, Sayegh MH, Coffman TM, Danovich GM, Krensky AM, Strom TB, Turka LA, Harmon WE: The allocation of cadaver Kidneys for transplantation in the United States: Consensus and controversy. *J. Am. Soc. Nephrol.* 1999; 10: 2237-2243.
173. Krensky AM: Guest Commentary. Transfer of specific unresponsiveness to organ allografts by thymocytes. *J. Am. Soc. Nephrol.* 1999; 10:2454-2463.
174. Bloom BR, Mazzaccaro RJ, Flynn J, Chan J, Sousa A, Salgame P, Stenger S, Modlin RL, Krensky A, Demant P, Kramni I: Immunology of an infectious disease: Pathogenesis and protection in tuberculosis. *The Immunologist* 1999; 7: 54-59.
175. Hanson D, Krensky AM: Granulysin and NK-lysin: Cytotoxic and antimicrobial proteins of cytolytic lymphocytes, In: Sitkovsky MV, Henkart PA, eds. *Cytotoxic Cells: Basic Mechanisms and Medical Applications*, Lippincott-Williams & Wilkins, Philadelphia, 2000; pp. 213-227.
176. Chen Y-F, Song A, Krensky AM: Transcriptional Regulation of Chemokines, In: Rothenberg ME, ed. *Chemokines in Allergic Disease*, Marcel Dekker, New York, 2000; pp. 115-136.
177. Krensky AM: Molecular biology of transplantation. *Nephron* 2000; 86: 260-5.
178. Sayegh MH, Krensky AM: Transplantation immunobiology, In: Owen WF, Periera BJG, Sayegh MH, eds. *Dialysis and Transplantation: A Companion to Brenner and Rector's The Kidney*, W.B. Saunders Co., Orlando, FL, 2000; pp. 487-498.
179. Krensky AM: Granulysin: A novel antimicrobial peptide of cytolytic T lymphocytes and natural killer cells. *Biochem Pharm.* 2000; 59: 317-320.
180. Krensky AM: Immune response to allografts. In Norman DJ, Turka T, eds., *The ASTP Primer on Transplantation*, 2nd Edition, American Society of Transplant Physicians, Thorofare, NJ. 2000; pp. 17-26.
181. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, Leslie DS, Lee HK, van Donselaar E, Hanson DA, Krensky AM, Majdic O, Porcelli SA, Morita CT, Brenner MB:

Self recognition of CD1 by $\gamma\delta$ T cells: implications for innate immunity. *J. Exp. Med.* 2000; 191: 937-948.

182. Sarwal M, Krensky AM: Costimulation. In Fine RN, Tejani A, eds., *Pediatric Solid Organ Transplantation*, Munksgaard, Copenhagen. 2000; pp. 26-34.

183. Ling X, Tamaki T, Xiao Y, Kamangar S, Clayberger C, Lewis DB, Krensky AM: An immunosuppressive and anti-inflammatory HLA class I derived peptide binds vascular cell adhesion molecule-1. *Transplantation* 2000; 70: 662-667.

184. Ling X, Kamangar S, Boytim ML, Kelman Z, Huie P, Lyu-S-C, Sibley RK, Hurwitz J, Clayberger C, Krensky AM: Proliferating cell nuclear antigen as the cell cycle sensor for an HLA derived peptide blocking T cell proliferation. *J. Immunol.* 2000; 164: 6188-6192.

185. Miyamoto NG, Medberry PS, Hesselgesser J, Boehlk S, Nelson PJ, Krensky AM, Perez HD: Interleukin-1 β induction of the chemokine RANTES promoter in the human astrocytoma line CH235. *J. Neuroimmunol.* 2000; 105: 78-90.

186. Boytim, M. L., Lilly, P., Drouvalakis, K., Lyu, S.-C., Jung, R., Krensky, A. M., Clayberger, C. A human class II derived peptide antagonizes phosphatidyl 3-kinase to block IL-2 signaling. *J. Clin. Invest.* 2000; 105:1447-1453.

187. Wang Z, Choice E, Kaspar A, Hanson D, Okada S, Lyu S-c, Krensky AM, Clayberger C: Bactericidal and tumoricidal activities of synthetic peptides derived from granulysin. *J. Immunol.* 2000; 165: 1486-90.

188. Ernst WA, Thoma-Uszynski S, Teitelbaum R, Ko C, Hanson DA, Clayberger C, Krensky AM, Leippe M, Bloom BR, Ganz T, Modlin RL: Granulysin, a T cell product, kills bacteria by altering membrane permeability. *J. Immunol.* 2000; 165: 7102-8.

189. Bluestone JA, Matthews JB, Krensky AM: The immune tolerance network: The "holy grail" comes to the clinic. *J. Am. Soc. Nephrol.* 2000; 11: 2141-6.

190. Song A, Nikolcheva T, Krensky AM: Transcriptional regulation of RANTES expression in T lymphocytes. *Immunol. Rev.* 2000; 177: 236-245.

191. Krensky AM, Clayberger C: The HLA-T-cell interaction in transplant rejection. In Stuart FP, Abecassis MM, Kaufman DB, eds., *Organ Transplantation*, Landes Bioscience, Georgetown, Tx, 2000; pp.435-445.

192. Murphy B, Krensky AM: HLA derived peptides as novel immunomodulatory therapeutics. In R. Duquesnoy and Y. Li, eds. *Clinical Transplantation Immunology*, Science Press, PR China, 2000; pp. 508-521.

193. Ochoa MT, Thoma-Uszynski S, Sieling PA, Sabet S, Krensky AM, Burdick A, Rhea TH, Modlin RL: Role of granulysin in immunity to leprosy. *Lepr. Rev.* 2000; S115-6.

194. Murphy B, Krensky AM: Immunomodulatory function of MHC peptides. In Sayegh M and Remuzzi G eds., *Current and Future Immunosuppression Therapies Following Transplantation*, Kluwer Academic Publishers, 2001; pp: 279-292.

195. Krensky AM, Clayberger C: Immunology and genetics of transplantation, In: Massry SG, Glasscock RJ, eds. Textbook of Nephrology Fourth Edition, Lippincott Williams and Wilkins, Philadelphia, 2001; pp. 1601-1610.
196. Clayberger C, Krensky AM: Mechanisms of allograft rejection. In Neilson EG, Couser WG, eds., Immunologic Renal Diseases, 2nd edition, Lippincott Williams and Wilkins, Philadelphia, 2001; pp 321- 346.
197. Stenger S, Krensky AM, Modlin RL: Granulysin, a novel mediator of antimicrobial activity of cytolytic T-cells. In Lohner K, ed. Development of novel antimicrobial agents: Emerging strategies, Horizon Scientific Press, Wymondham, UK, 2001; pp. 61-69.
198. Krensky AM. Strom TB, Bluestone JA: Immunomodulators: Immunosuppressive Agents, Tolerogens, and Immunostimulants, In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill, Philadelphia, 2001; pp. 1463-1484.
199. Sarwal M, Jani A, Chang S, Huie P, Wang Z, Salvatierra O, Clayberger C, Sibley R, Krensky AM, Pavlakis M: Granulysin expression is a marker for acute rejection and steroid resistance in human renal transplantation. Human Immunology 2001; 62: 21-31.
200. Hata A, Zerboni L, Sommer M, Kaspar AA, Clayberger C, Krensky AM, Arvin AM: Granulysin blocks viral replication and triggers apoptosis in infected cells. Viral Immunology 2001; 14: 125-133.
201. Horuk R, Clayberger C, Krensky AM, Wang Z, Grone H-J, Weber C, Weber KSC, Nelson PJ, May K, Rosser M, Dunning L, Liang M, Buckman B, Ghannam A, Ng HP, Islam I, Bauman JG, Wei G-P, Monahan S, Xu W, Snider RM, Morrissey MM, Hesselgesser J, Perez HD: A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem. 2001; 276: 4199-4204.
202. Ochoa MT, Stenger S, Seiling PA, Thoma-Uszynski S, Sabet S, Cho S, Krensky AM, Rollinghoff M, Nunos Sarno E, Burdick A, Rea TH, Modlin RL: T cell release of granulysin contributes to host defense in leprosy. Nature Medicine 2001; 7: 174-179.
203. Kaspar AA, Poulain FR, Kelekar A, Hanson DA, Hitoshi Y, Johnson DE, Froelich C, Thompson CB, Anel A, Clayberger C, Krensky AM: A distinct pathway of cell-mediated apoptosis initiated by granulysin. 2001. J. Immunol. 167: 350-356.
204. Kumar J, Okada S, Clayberger C, Krensky AM: Granulysin: A novel antimicrobial. Exp. Opin. Invest. Drugs 2001; 10: 321-330.
205. Krensky AM, Pober JS: Immunologic frontiers of transplantation. Immunity 2001; 14: 345-346.
206. Nelson PJ, Krensky AM: Chemokines, chemokine receptors, and allograft rejection. Immunity 2001; 14: 377-386.
207. Krensky AM: Immunologic Tolerance. Ped. Nephrol. 2001; 16: 675-9.
208. Pardo J, Perez-Galan P, Gamen S, Marzo I, Monleon I, Kaspar A, Susin SA, Kroemer G, Krensky AM, Naval J, Anel A: A role of the mitochondrial apoptosis inducing factor (AIF) in granulysin-induced apoptosis. J. Immunol. 2001; 167: 1222-1229.

209. Nelson PJ, Krensky AM: Chemokines and allograft rejection; narrowing the list of suspects. *Transplantation* 2001; 72: 1195-7.
210. Dieli F, Troye-Blomberg M, Ivanyi J, Fournié JJ, Krensky AM, Bonneville M, Peyrat MA, Caccamo N, Sireci G, Salerno A: Granulysin-dependent killing of intracellular and extracellular *Mycobacterium tuberculosis* by V γ 9/V δ 2 T lymphocytes. *J. Infect. Dis.* 2001; 184: 1082-5.
211. Schubert LA, Cron RQ, Cleary AM, Song A, Lu L-S, Jullien P, Krensky AM, Lewis DB: A T cell specific enhancer of the human CD40 ligand gene. *J. Biol. Chem.* 2002; 277: 7386-95.
212. Jiang Y, Chen D, Lyu S-C, Ling X, Krensky AM, Clayberger C: DQ 65-79, a peptide derived from HLA Class II, induces I κ B expression. *J. Immunol.* 2002; 168: 3323-8.
213. Caccamo N, Milano S, Di Sano C, Cigna D, Ivanyi J, Krensky AM, Dieli F, Salerno A: identification of epitopes of *Mycobacterium tuberculosis* 16kDa protein recognized by human leukocyte antigen A*0201 CD8+ T lymphocytes. *J. Infec. Dis.* 2002; 186:991-8.
214. Nikolcheva T, Pyronnet S, Chou S-y, Sonenberg N, Song A, Clayberger C, Krensky AM: A translational rheostat for RFLAT-1 regulates RANTES expression in T lymphocytes. *J. Clin. Invest.* 2002; 110: 119-26.
215. Song A, Patel A, Thamatrakoln K, Liu C, Feng D, Clayberger C, Krensky AM: Functional domains and DNA-binding sequences of RFLAT-1/KLF13, a Kruppel-like transcription factor of activated T lymphocytes. *J. Biol. Chem.* 2002; 277: 30055-30065.
216. Ma LL, Spurrell JCL, Wang JF, Neely GG, Epelman S, Krensky AM, Mody CH: CD8 T cell-mediated killing of *Cryptococcus neoformans* requires granulysin and is dependent on CD4 T cells and IL-15. *J. Immunol.* 2002; 169: 5787-5795.
217. Dieli F, Sireci G, Caccamo N, Di Sano C, Titone L, Romano A, DiCarlo P, Barera A, Accardo-Palumbo A, Krensky AM, Salerno A: Selective depression of interferon-gamma and granulysin production with increase of proliferative response by V gamma 9/V delta 2 T cells in children with tuberculosis. *J. Inf. Dis.* 2002; 186: 1835-1839.
218. Gansert J, Kiessler V, Engele M, Wittke F, Rollinghoff M, Krensky AM, Porcelli S, Modlin RL, Stenger S: Human NKT cells express granulysin and exhibit antimycobacterial activity. *J. Immunol.* 2003; 170: 3154-3161.
219. Krensky AM: First Principles. 2002 SPR Presidential Address. *Ped. Res.* 2003; 53: 513-515.
220. Samten B, Wizel B, Weis SE, Shams H, Klucar P, Wu S, Vankayalapati R, Thomas EK, Okada S, KrenskyAM, Barnes PF: CD40 ligand trimer enhances the response of CD8+ T cells to *mycobacterium tuberculosis*. *J. Immunol.* 2003; 170: 3180-3186.
221. Mori N, Krensky AM, Geleziunas R, Wada A, Hirayama T, Sasakawa C, Yamamoto N: *helicobacter pylori* induces RANTES through activation of NF-kB. *Infect. Immun.* 2003; 71:3748-3756.

222. Anderson DH, Sawaya MR, Cascio D, Ernst W, Modlin R, Krensky A, Eisenberg D: Granulysin crystal structure and structure-derived lytic mechanism. *J. Mol. Biol.* 2003; 325: 355-365.
223. Okada S, Li Q, Whitin JC, Clayberger C, Krensky AM: Intracellular mediators of granulysin-induced cell death. *J. Immunol.* 2003; 171: 2556-2562.
224. Clayberger C, Krensky AM: Granulysin. *Curr Opin Immunol.* 2003; 15: 560-565.
225. Dong C, Lyu S-C, Krensky AM, Clayberger C: DQ65-79, a peptide derived from HLA class II, mimics p21 to block T cell proliferation. *J. Immunol.* 2003; 171: 5064-5070.
226. Krensky AM, Clayberger C: Transplantation Immunobiology, In: Avner ED, Harmon W and Niaudet P, eds. *Pediatric Nephrology*, 5th Ed, Lippincott Williams & Wilkins, Baltimore, 2004; pp. 1411-1436.
227. Raychaudhuri SP, Jiang WY, Raychaudhuri SK, Krensky AM. Lesional T cells and dermal dendrocytes in psoriasis plaque express increased levels of granulysin: A controlling factor for secondary infections. *J Am Acad Dermatol* 2004. In press.
228. Farouk S., Mincheva-Nilsson L, Krensky AM, Dieli F, Troye-Blomberg M: Gamma, delta T cells inhibit the in vitro growth of the asexual blood stages of plasmodium falciparum by a granule exocytosis pathway that requires granulysin. *Eur. J. Immunol.* 2004; 34: 2248-2256.
229. Ma LL, Wong C, Neely GG, Epelman S, Krensky AM, Mody CH: NK cells utilize perforin, rather than granulysin, for anticryptococcal activity. *J. Immunol.* 2004; 173: 3357-3365.
230. Najafian N, Krensky AM, Sayegh MH: Transplantation Immunobiology. In: Periera BJG, Sayegh MH, Blake P, eds. *Chronic Kidney Disease: Dialysis and Transplantation*, 2nd Edition, Elsevier, Philadelphia; pp. XXX-XXX, in press.
231. Li Q, Dong C, Deng A, Katsumata M, Nakadai A, Kawada T, Okada S, Clayberger C, Krensky AM: Hemolysis of erythrocytes by granulysin derived peptides but not by granulysin. *Antimicrobial Agents and Chemotherapy*. 2004. In press.
232. Clayberger C, Krensky AM: T cell and NK cell immunity, In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. *Hematology: Basic Principles and Practice*, 4th Edition, Churchill Livingstone, New York, 2003; in press.
233. Mori N, Krensky AM, Ohshima K, Yamada Y, Ikeda S, Tomonaga M, Geleziunas R, Yamamoto N: Elevated expression of CCL5/RANTES in adult T-cell leukemia cells: Possible transactivation of the CCL5 gene by human T-cell leukemia virus type I TAX. *Int. J. Cancer* 2004; 111:548-557.
234. Krensky AM. Vincenti F, Bennett W: Immunomodulators: Immunosuppressive Agents, Tolerogens, and Immunostimulants, In: Brunton LL, ed. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 11th Edition, McGraw-Hill, Philadelphia, 2005; in press.

235. Feng D, Song A, Dong C, McPherson L, Lyu S-c, Zhou L, Shi L, Ahn Y-T, Wang D, Clayberger C, Krensky AM: Regulation of RANTES expression and cell death in T lymphocytes by the transcription factor, KLF13. Submitted.
236. Komazawa N, Kataoka TR, Li Q, Krensky AM, Morimoto K: A novel method to evaluate the effects of immunotoxic chemicals on natural killer activity. Submitted
237. Uchihara J, Krensky AM, Matsuda T, Kawakami H, Ohta T, Takasu N, Mori N: Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. *Int. J. Cancer* 2004; in press.
238. Li Q, Nakadai A, Morimoto K, Krensky AM, Kawada T: Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly decreases the expression of perforin, granzymes A and granulysin in NK-92CI cell line. Submitted.
239. Dong C, Li Q, Lyu S-c, Krensky AM, Clayberger C: A novel apoptosis pathway activated by the carboxyl terminus of p21. *Blood* 2004; in press.
240. Gantzios R, McPherson L, Johansen T, Song A, Clayberger C, Krensky AM: Stromelysin promoter binding protein coactivates RANTES transcription in late activated T lymphocytes. Submitted
241. Deng A, Chen S, Li Q, Lyu S-c, Clayberger C, Krensky AM: Granulysin , a cytolytic molecule, is also a chemoattractant and proinflammatory activator. Submitted.
242. Di Liberto D, Buccheri S, Caccamo N, Meraviglia S, Dieli F, Krensky AM, Salerno A: A novel ELISA for detecting serum granulysin and application to tuberculosis. Submitted.

RESEARCH SUPPORT

ACTIVE

R37 DK35008-21 MERIT AWARD	Krensky, A. (PI)	07/01/84 – 04/30/07
NIH	25%	\$270,012 direct \$421,743 total

Antigens in CTL Mediated Transplant Rejection

The major goal of this project is to determine the transcriptional and translational regulation of expression of late T cell activation gene RANTES.

R01 AI43348-05	Krensky, A. (PI)	07/01/98 – 05/31/07
NIH	25%	\$291,000 direct \$457,311 total

Granulysin, a Novel Cytolytic Molecule

This project investigates the expression, regulation, and lytic mechanisms of granulysin.

U19 AI056548-01	Clayberger, C. (PI) Krensky, A. (Project 2 PI)	10/01/03 – 12/31/07
NIH	15%	\$1,357,160 direct \$ 223,717 proj 2 direct

Granulysin Derived Immunotherapeutics for Biodefense

The major goal of this program is to develop novel immunotherapeutics based on granulysin peptides for biodefense and for treatment of antibiotic resistant pathogens.

RO1 AI50187-02	Clayberger, C. (PI) Krensky, A. (Co-PI)	09/15/02 – 03/31/05
NIH	15%	\$200,000 direct

HLA Derived Peptides in Transplantation

The major goal of this project is to elucidate the mechanism of action of HLA derived tolerogenic peptides.

RO1 AIO51356-01	Clayberger, C. (PI) Krensky, A. (Co-PI)	12/01/02 – 11/30/07
NIH	10%	\$250,000 direct

M. Tuberculosis CTL Epitopes: Vaccine Design/Evaluation

The long term goal of this proposal is to characterize the T cell immune response to a selected group of proteins from Mycobacterium tuberculosis (Mtb) in order to identify correlates with protective immunity and to apply this information to the development of improved tuberculosis (TB) vaccines.